How Does Lipitor Work on Proteins?
Lipitor (atorvastatin) inhibits HMG-CoA reductase, a key enzyme in the liver that produces cholesterol. This protein converts HMG-CoA to mevalonate, the rate-limiting step in the mevalonate pathway. By blocking it competitively, Lipitor lowers LDL cholesterol and triglycerides.[1]
Which Proteins Transport or Metabolize Lipitor?
Lipitor interacts with several transporters and metabolizing enzymes:
- CYP3A4: Primary cytochrome P450 enzyme that metabolizes Lipitor into active and inactive forms. Strong inhibitors like itraconazole or clarithromycin raise Lipitor levels, increasing muscle toxicity risk.[1][2]
- OATP1B1 (SLCO1B1): Uptake transporter in liver cells that brings Lipitor inside hepatocytes. Genetic variants or drugs like gemfibrozil reduce its function, elevating blood levels and side effect risks.[2]
- BCRP (ABCG2): Efflux pump that limits intestinal absorption; inhibitors like omeprazole can boost exposure.[2]
What Genetic Protein Variants Affect Lipitor Response?
Polymorphisms in these proteins influence efficacy and safety:
- SLCO1B1 variants (e.g., *5 allele) impair OATP1B1 transport, raising myopathy risk—FDA warns of up to 4-fold increase.[3]
- CYP3A4/5 or ABCG2 changes alter metabolism, affecting cholesterol reduction in some patients.[1][3]
Do Other Proteins Modulate Lipitor's Cholesterol Effects?
Lipitor indirectly impacts proteins downstream of HMG-CoA reductase:
- Reduces PCSK9 levels, enhancing LDL receptor recycling on liver cells for better cholesterol clearance.[1]
- Lowers RhoA prenylation, a mevalonate byproduct, which affects vascular smooth muscle proteins and may contribute to plaque stabilization.[4]
[1]: DrugPatentWatch.com - Atorvastatin
[2]: FDA Label - Lipitor
[3]: Clinical Pharmacogenetics Implementation Consortium Guidelines for SLCO1B1
[4]: Nature Reviews Drug Discovery - Statins mechanism review